About Provention Bio
Provention Bio is a Healthcare company based in United States founded in 2016 by Ashleigh Palmer and Francisco Leon, and was acquired by Sanofi in March 2023. Investigational immunomodulatory therapies for immune-mediated diseases are developed. Provention Bio has raised $28.45 million across 3 funding rounds from investors including Sanofi, Armistice Capital and Johnson & Johnson Innovation. Its chief executive, as recorded, is Ashleigh Palmer. Provention Bio offers products and services including Prescription Products, Vaccine Products, and Consumer Health Products. Its focus areas include Life Sciences, Immunology, Drugs and Diversified. Its competitors include Biogen, ADMA Biologics and Kymeratx; 3 of its 3 listed competitors have raised funding.
Company details
Provention Bio was founded in 2016 and is located in Hunterdon, United States. Investigational immunomodulatory therapies are developed to intercept and prevent immune-mediated diseases. A pipeline targeting autoimmune conditions, including type 1 diabetes, celiac disease, and lupus, is advanced within the biotechnology sector. Operations center on therapeutic solutions for immune disorders, with a focus on clinical-stage development in the United States.
- Headquarters Hunterdon, United States
- Founders Ashleigh Palmer, Francisco Leon
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website proventionbio.com
- Social LinkedIn YouTube
- Acquired by Sanofi (Mar 2023)
Products & Services of Provention Bio
Provention Bio offers a comprehensive portfolio of products and services, including Prescription Products, Vaccine Products, and Consumer Health Products.
Medicines for immunology and oncology treatments
Vaccines against influenza and respiratory viruses
OTC items for everyday health needs
Apps and channels of Provention Bio
its YouTube channel Sanofi US has 2.18K subscribers and 30 videos.
Videos from Provention Bio
The most watched videos on Provention Bio's YouTube channel, Sanofi US (2.18K subscribers). Click a video to play it here.
More on Sanofi US.
Funding Insights of Provention Bio
Provention Bio has successfully raised a total of $28.45M across 3 strategic funding rounds. The most recent funding activity was a Post-IPO round of $35 million completed in February 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $28.45M
- Total Rounds 3
- Last Round Post-IPO — $35M
- First Round $28.45M
(May 2017)
- Investors Count 4
All 3 funding rounds of Provention Bio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2023 | $35M | Post-IPO | – | – | |
| Jul 2022 | $60M | Post-IPO | – | – | |
| May 2017 | $28.45M | Series A | – | Johnson & Johnson Innovation, T1D Fund | – |
4 investors in total: 4 institutional.
Investors in Provention Bio
Provention Bio has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include Sanofi, Armistice Capital and Johnson & Johnson Innovation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Companies developing T1D products are funded through venture philanthropy. | t1dfund.org | Boston, United States | ||
Pharmaceutical and nutraceutical products are developed across seven therapeutic areas. | 1973 | sanofi.com | Paris, France | |
Global hedge fund managing long/short investments in health care and consumer sectors. | 2012 | armisticecapital.com | New York, United States | |
| jnjinnovation.com |
Investor details for Provention Bio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Provention Bio
62 people are tracked at Provention Bio (38 in leadership, 5 in board & advisors, 19 in team).
| Name | Role | Group |
|---|---|---|
Ashleigh Palmer | Co-Founder & CEO | Leadership |
Francisco Leon | Co-Founder | Leadership |
Sandee Merrick | Director National Accounts West- Market Access- Provention Bio | Leadership |
Waleed A. | Market Access Director | Leadership |
Steven Hogan | Regional Sales Director | Leadership |
Kaela Goldstein | Director, Clinical Operations | Leadership |
Kristin Neff | Vice President Clinical Operations | Leadership |
Thierry Chauche | Chief Financial Officer | Leadership |
Christina Yi | Chief Operations Officer | Leadership |
Dan Pelagalli | Regional Sales Director, Great Lakes | Leadership |
Lulu McCartin | Vice President Of Commercial Operations | Leadership |
Rachel Garner | Executive Director, Clinical Science | Leadership |
Wei Tian | Vice President, Head of Biometrics | Leadership |
Paul Dunford | Vice President, Translational Medicine & Science | Leadership |
Miguel Sanjuan | Senior Vice President, Research and Early Development | Leadership |
Philip Ball | Vice President, Alliance Management and Business Development | Leadership |
Sarah Baxter | Medical Director | Leadership |
Edward (Ed) Kawamura | Vice President | Leadership |
Kaelan H. | Vice President of Communications | Leadership |
Linda M. Arterburn, PhD | Vice President Regulatory Affairs | Leadership |
42 more people are available in the full profile.
Complete people profiles for Provention Bio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Provention Bio
5 dated milestones of Provention Bio across 7 years, from founding to its latest funding, stage changes and deals.
- Founded Provention Bio is founded.
- Funding First funding round of $28.5M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $35.0M.
- Exit Acquired by Sanofi.
Competitors of Provention Bio
Provention Bio has 3 listed competitors in our database, 3 of them funded. They include Biogen, ADMA Biologics and Kymeratx.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| biogen.com | 1978 | Cambridge, United States | $80M | 1 | Therapies for neurodegenerative and immunology disorders are developed. | |
| admabiologics.com | 2005 | Ramsey, United States | $17.55M | 498 | Plasma-based biologics are developed for immune deficiency and infectious diseases. | |
| kymeratx.com | 2016 | Cambridge, United States | $197M | 150 | Small molecule protein degraders are developed for various disorders. |
Detailed competitors of Provention Bio
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as Provention Bio (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Provention Bio
Complete news archive for Provention Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Provention Bio
Provention Bio was founded in 2016 and raised its 1st funding round 1 year after it was founded.
Provention Bio is headquartered in United States. It is registered at New Jersey, United States.
Ashleigh Palmer is the CEO of Provention Bio, as recorded in our data. They have also founded this company.
Provention Bio is a funded company, having raised a total of $28.45M across 3 funding rounds to date. The company's 1st funding round was a Series A of $28.45M, raised on May 2017.
Provention Bio was founded in 2016 and is located in Hunterdon, United States. Investigational immunomodulatory therapies are developed to intercept and prevent immune-mediated diseases. A pipeline targeting autoimmune conditions, including type 1 diabetes, celiac disease, and lupus, is advanced within the biotechnology sector. Operations center on therapeutic solutions for immune disorders, with a focus on clinical-stage development in the United States.
Provention Bio's top competitors include ADMA Biologics, Kymeratx and Biogen.
Provention Bio offers Prescription Products, Vaccine Products, and Consumer Health Products.
Provention Bio has 4 investors. Key investors include Sanofi, Armistice Capital, Johnson & Johnson Innovation, and T1D Fund.
Yes. Provention Bio was acquired by Sanofi in March 2023.